UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $449.00 million. The enterprise value is $317.53 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, before market open.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 42.20 million shares outstanding. The number of shares has increased by 46.48% in one year.
| Current Share Class | 42.20M |
| Shares Outstanding | 42.20M |
| Shares Change (YoY) | +46.48% |
| Shares Change (QoQ) | +17.05% |
| Owned by Insiders (%) | 5.52% |
| Owned by Institutions (%) | 74.77% |
| Float | 32.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.45 |
| Forward PS | 3.99 |
| PB Ratio | 17.59 |
| P/TBV Ratio | 17.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.00, with a Debt / Equity ratio of 4.81.
| Current Ratio | 9.00 |
| Quick Ratio | 8.31 |
| Debt / Equity | 4.81 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.85 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.12% |
| Return on Capital (ROIC) | -50.64% |
| Revenue Per Employee | $444,592 |
| Profits Per Employee | -$574,020 |
| Employee Count | 201 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.38 |
Taxes
In the past 12 months, UroGen Pharma has paid $4.04 million in taxes.
| Income Tax | 4.04M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.54% in the last 52 weeks. The beta is 1.07, so UroGen Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -29.54% |
| 50-Day Moving Average | 12.05 |
| 200-Day Moving Average | 13.92 |
| Relative Strength Index (RSI) | 29.98 |
| Average Volume (20 Days) | 400,458 |
Short Selling Information
The latest short interest is 5.77 million, so 13.68% of the outstanding shares have been sold short.
| Short Interest | 5.77M |
| Short Previous Month | 6.44M |
| Short % of Shares Out | 13.68% |
| Short % of Float | 17.85% |
| Short Ratio (days to cover) | 12.42 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $89.36 million and -$115.38 million in losses. Loss per share was -$3.08.
| Revenue | 89.36M |
| Gross Profit | 80.67M |
| Operating Income | -83.73M |
| Pretax Income | -100.36M |
| Net Income | -115.38M |
| EBITDA | -83.28M |
| EBIT | -83.73M |
| Loss Per Share | -$3.08 |
Full Income StatementBalance Sheet
The company has $249.58 million in cash and $122.75 million in debt, giving a net cash position of $131.47 million or $3.12 per share.
| Cash & Cash Equivalents | 249.58M |
| Total Debt | 122.75M |
| Net Cash | 131.47M |
| Net Cash Per Share | $3.12 |
| Equity (Book Value) | 25.52M |
| Book Value Per Share | 0.60 |
| Working Capital | 262.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$96.14 million and capital expenditures -$236,000, giving a free cash flow of -$96.38 million.
| Operating Cash Flow | -96.14M |
| Capital Expenditures | -236,000 |
| Free Cash Flow | -96.38M |
| FCF Per Share | -$2.28 |
Full Cash Flow StatementMargins
Gross margin is 90.27%, with operating and profit margins of -93.70% and -129.11%.
| Gross Margin | 90.27% |
| Operating Margin | -93.70% |
| Pretax Margin | -124.59% |
| Profit Margin | -129.11% |
| EBITDA Margin | -93.20% |
| EBIT Margin | -93.70% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -46.48% |
| Shareholder Yield | -46.48% |
| Earnings Yield | -25.70% |
| FCF Yield | -21.47% |
Analyst Forecast
The average price target for UroGen Pharma is $44.50, which is 318.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.50 |
| Price Target Difference | 318.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 49.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -2.04 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.04 |
| Piotroski F-Score | 3 |